Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.65 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TOP2A | P11388 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14616208 | 0.81 | ALDH1A1 (0.44) | HSD17B10MAPTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5256298 | 0.81 | HSD17B10 (0.44) | HSD17B10MAPTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1218749 | 0.79 | HSD17B10 (1.00) | HSD17B10CHEK1MAPTKDM4EALDH1A1 | |
| SCHEMBL31529600 | 0.79 | HSD17B10 (1.00) | HSD17B10CHEK1MAPTKDM4EALDH1A1 | |
| SCHEMBL3380916 | 0.78 | HSD17B10 (0.65) | HSD17B10CHEK1MAPTKDM4EALDH1A1 | |
| SCHEMBL4361327 | 0.76 | DDAH1 (0.55) | MAPTKDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL29419554 | 0.76 | SMN1; SMN2 (0.49) | HSD17B10CHEK1MAPTKDM4EALDH1A1 | |
| SCHEMBL4743261 | 0.76 | HSD17B10 (0.69) | HSD17B10MAPTKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5879697 | 0.74 | SMN1; SMN2 (0.43) | MAPTKDM4EALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL10514181 | 0.73 | MAPT (0.37) | MAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303182-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | NOVARTIS AG (CH) | 2014-10-09 | — | — | US | disclosed |
| EP-2762475-A1 | Pharmaceutically acceptable salts of quinolinone compounds and their medical use | Novartis Vaccines and Diagnostics, Inc. (US) | 2014-08-06 | — | — | EP | disclosed |
| US-20130338171-A1 | Pharmaceutically Acceptable Salts of Quinolinone Compounds Having Improved Pharmaceutical Properties | NOVARTIS AG (CH) | 2013-12-19 | — | — | US | disclosed |
| EP-2573079-A2 | Benzimidazole quinolinones and uses thereof | Novartis Vaccines and Diagnostics, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20130018058-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | CAI SHAOPEI (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130018058-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | CAI SHAOPEI (US) | 2013-01-17 | — | — | US | disclosed |
| EP-1497287-B1 | Quinoline derivatives in combination with 5-FU or CPT-11 for use in the treatment of cancer | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7825132-B2 | Inhibition of FGFR3 and treatment of multiple myeloma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825132-B2 | Inhibition of FGFR3 and treatment of multiple myeloma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20100184754-A1 | QUINOLINONE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-07-22 | — | — | US | disclosed |
| WO-2003087095-A1 | QUINOLINONE DERIVATIVES | CHIRON CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
| US-20030158224-A1 | Quinolinone derivatives | CHIRON CORPORATION | 2003-08-21 | — | — | US | disclosed |
| US-6605617-B2 | Treating a patient in need of an inhibitor of vascular endothelial growth factor receptor tyrosine kinase | CHIRON CORPORATION | 2003-08-12 | — | — | US | disclosed |
| EP-1317442-A1 | QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-06-11 | — | — | EP | disclosed |
| EP-1313734-A2 | AZA HETEROCYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE | CHIRON CORPORATION (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20030028018-A1 | Quinolinone derivatives | CHIRON COPORATION | 2003-02-06 | — | — | US | disclosed |
| US-20020107392-A1 | Quinolinone derivatives | NOVARTIS AG (CH) | 2002-08-08 | — | — | US | disclosed |
| US-20020103230-A1 | Heterocyclic compounds | CHIRON CORPORATION | 2002-08-01 | — | — | US | disclosed |
| WO-2002022598-A1 | QUINOLINONE DERIVATIVES AS TYROSINE KINASE INHIBITORS | CHIRON CORPORATION (US) | 2002-03-21 | — | — | WO | disclosed |
| WO-2002018383-A2 | AZA HETEROCYCLIC DERIVATIVES AND THEIR THERAPEUTIC USE | CHIRON CORPORATION (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103230-A1 | Heterocyclic compounds | SLCO2A1, SLCO1B1, SLCO2B1 | HSD17B10 793/4885CHEK1 4225/4885MAPT 3261/4885 |
| US-20030028018-A1 | Quinolinone derivatives | SLCO1B1, SLCO1B3, SLCO1A2 | HSD17B10 540/4885CHEK1 3389/4885MAPT 2067/4885 |
| US-20130338171-A1 | Pharmaceutically Acceptable Salts of Quinolinone Compounds Having Improved Pharmaceutical Properties | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | HSD17B10 1495/4885CHEK1 3620/4885MAPT 5/4885 |
| US-20030158224-A1 | Quinolinone derivatives | SLCO1B1, SLCO1B3, SLCO1A2 | HSD17B10 540/4885CHEK1 3389/4885MAPT 2067/4885 |
| US-20020107392-A1 | Quinolinone derivatives | SLCO1B1, SLCO1B3, SLCO1A2 | HSD17B10 540/4885CHEK1 3389/4885MAPT 2067/4885 |
| US-20100184754-A1 | QUINOLINONE DERIVATIVES | SLCO1B1, SLCO1B3, SLCO1A2 | HSD17B10 498/4885CHEK1 3447/4885MAPT 1907/4885 |
| US-20140303182-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | HSD17B10 1495/4885CHEK1 3620/4885MAPT 5/4885 |
| US-20130018058-A1 | PHARMACEUTICALLY ACCEPTABLE SALTS OF QUINOLINONE COMPOUNDS HAVING IMPROVED PHARMACEUTICAL PROPERTIES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RAB14, SLC13A3 | HSD17B10 1495/4885CHEK1 3620/4885MAPT 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.